Matthew E. Ros

Chief Strategy and Business Officer of Epizyme, Inc.

Mr. Ros currently serves as Chief Strategy and Business Officer at Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies. He has more than 25 years of experience with global pharmaceutical and early-stage biotechnology companies, building and leading teams across sales, marketing, franchise strategy and operations. Prior to joining Epizyme, Mr. Ros served as Chief Operating Officer and Global Head of the Oncology Business Unit at Sanofi-Genzyme and held leadership positions at ARIAD Pharmaceuticals. Mr. Ros began his career at Bristol-Myers Squibb, where he held positions of increasing responsibility in its Oncology division, contributing to the successful launches of TAXOL, ERBITUX®, SPRYCEL® and IXEMPRA®.  Mr. Ros previously served on the Board of Trustees of CancerCARE, a leading national organization dedicated to providing free, professional support services to people affected by cancer.

Matthew E. Ros